Literature DB >> 16809307

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Zixin Hu1, Françoise Giguel, Hiroyu Hatano, Patrick Reid, Jing Lu, Daniel R Kuritzkes.   

Abstract

Resistance to zidovudine (ZDV) results from thymidine analog resistance mutations (TAMs) at human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) codons 41, 67, 70, 210, 215, and 219. Two mutations are possible at codon 215: Y or F. Whereas T215Y occurs alone or with M41L and L210W (TAM-1 pattern), T215F rarely occurs with these mutations or by itself; it is found instead with D67N, K70R, and K219Q (TAM-2 pattern). The L210W mutation most often occurs with M41L and T215Y and rarely occurs with the T215F or TAM-2 mutation. To explain these associations, TAMs were introduced into HIV-1(Hxb2) by site-directed mutagenesis and expressed in recombinant viruses. Viral replication kinetics, relative fitness, and infectivity were tested in the absence or presence of ZDV. Viruses carrying the 215Y mutation showed faster replication kinetics and greater relative fitness than did T215F mutants in the absence or presence of ZDV. In addition, T215Y mutants showed greater infectivity than did wild-type HIV-1 over a range of ZDV concentrations, but T215F mutants had only a modest advantage over the wild-type virus. Whereas introduction of L210W improved the relative fitness of an M41L/T215Y mutant in the presence of ZDV, introduction of this mutation into a D67N/K70R/K219Q background resulted in decreased relative fitness in the presence or absence of drug. By contrast, introduction of T215F into the D67N/K70R/K219Q background increased viral fitness in the presence of ZDV. These results help explain why T215Y but not T215F usually emerges as the first major TAM, as well as the clustering of L210W with TAM-1 mutations and T215F with TAM-2 mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809307      PMCID: PMC1489059          DOI: 10.1128/JVI.02747-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.

Authors:  H M Precious; H F Günthard; J K Wong; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman; A J Leigh Brown
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

2.  A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.

Authors:  J Lu; D R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

3.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.

Authors:  N Yahi; C Tamalet; C Tourrès; N Tivoli; F Ariasi; F Volot; J A Gastaut; H Gallais; J Moreau; J Fantini
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; A J Brown; A V Savara; J D Hazelwood; R T D'Aquila
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.

Authors:  N Yahi; C Tamalet; C Tourrès; N Tivoli; J Fantini
Journal:  J Biomed Sci       Date:  2000 Nov-Dec       Impact factor: 8.410

9.  Antiretroviral-drug resistance among patients recently infected with HIV.

Authors:  Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

10.  Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.

Authors:  P P Chamberlain; J Ren; C E Nichols; L Douglas; J Lennerstrand; B A Larder; D I Stuart; D K Stammers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more
  29 in total

1.  Predicting resistance mutations using protein design algorithms.

Authors:  Kathleen M Frey; Ivelin Georgiev; Bruce R Donald; Amy C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 3.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

5.  Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.

Authors:  Kimberly L Armstrong; Tun-Hou Lee; M Essex
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

6.  Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.

Authors:  Szu-Min Hsieh; Sung-Ching Pan; Sui-Yuan Chang; Chien-Ching Hung; Wang-Huei Sheng; Mao-Yuan Chen; Shan-Chwen Chang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-15       Impact factor: 2.205

7.  The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.

Authors:  J Wang; H Liang; L Bacheler; H Wu; K Deriziotis; L M Demeter; C Dykes
Journal:  Virology       Date:  2010-04-18       Impact factor: 3.616

8.  Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.

Authors:  Paul L Boyer; Kalyan Das; Eddy Arnold; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 9.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

10.  Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.